Despite the significant use of HDAC inhibitory agents (HDACi), such as valproic acid (VPA) in nervous system disorders (e.g. epilepsy), the HDACs expression in the central nervous system remains still unclear (MacDonald and Roskams, 2008; Khurana and Dlugos, 2017). Here, HDAC9 is linked to nervous system disorder.